Larimar Therapeutics, Inc.2024财年第二财季实现净利润-21.63百万美元，同比减少158.42%

自选股智能写手08-17

8月17日，Larimar Therapeutics, Inc.（LRMR.US）公布财报，公告显示公司2024财年第二财季净利润为-21.63百万美元，同比减少158.42%；其中营业收入为0.00美元，每股基本收益为-0.34美元。从资产负债表来看，Larimar Therapeutics, Inc.（LRMR.US）总负债25.76百万美元，其中短期债务992000.00美元，资产负债比为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460241545?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-17 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460241545","market":"us","top_or_hot":-1,"title":"Larimar Therapeutics, Inc.2024财年第二财季实现净利润-21.63百万美元，同比减少158.42%","media":"自选股智能写手","content":"<div>\n<p>8月17日，Larimar Therapeutics, Inc.（LRMR.US）公布财报，公告显示公司2024财年第二财季净利润为-21.63百万美元，同比减少158.42%；其中营业收入为0.00美元，每股基本收益为-0.34美元。从资产负债表来看，Larimar Therapeutics, Inc.（LRMR.US）总负债25.76百万美元，其中短期债务992000.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000615959f2d63&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Larimar Therapeutics, Inc.2024财年第二财季实现净利润-21.63百万美元，同比减少158.42%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLarimar Therapeutics, Inc.2024财年第二财季实现净利润-21.63百万美元，同比减少158.42%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-17 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000615959f2d63&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月17日，Larimar Therapeutics, Inc.（LRMR.US）公布财报，公告显示公司2024财年第二财季净利润为-21.63百万美元，同比减少158.42%；其中营业收入为0.00美元，每股基本收益为-0.34美元。从资产负债表来看，Larimar Therapeutics, Inc.（LRMR.US）总负债25.76百万美元，其中短期债务992000.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000615959f2d63&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000615959f2d63&s=b","article_id":"2460241545","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000615959f2d63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460241545","pubTimestamp":1723824038,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月17日，Larimar Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-21.63百万美元，同比减少158.42%；其中营业收入为0.00美元，每股基本收益为-0.34美元。从资产负债表来看，Larimar Therapeutics, Inc.总负债25.76百万美元，其中短期债务992000.00美元，资产负债比为0.10，流动比率为0.11。机构评级：截至2024年8月17日，当前有6家机构对Larimar Therapeutics, Inc.目标价做出预测，其中目标均价为22.35美元，其中最低目标价为9.12美元，最高目标价为36.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","LRMR":"Larimar Therapeutics, Inc."},"translate_title":"Larimar Therapeutics, Inc. achieved a net profit of-US $21.63 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 158.42%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"LRMR":1},"content_text":"8月17日，Larimar Therapeutics, Inc.（LRMR.US）公布财报，公告显示公司2024财年第二财季净利润为-21.63百万美元，同比减少158.42%；其中营业收入为0.00美元，每股基本收益为-0.34美元。从资产负债表来看，Larimar Therapeutics, Inc.（LRMR.US）总负债25.76百万美元，其中短期债务992000.00美元，资产负债比为0.10，流动比率为0.11。机构评级：截至2024年8月17日，当前有6家机构对Larimar Therapeutics, Inc.目标价做出预测，其中目标均价为22.35美元，其中最低目标价为9.12美元，最高目标价为36.00美元。公司简介：Larimar Therapeutics Inc 是一家处于临床阶段的生物技术公司，专注于利用新型细胞穿透肽技术平台为复杂罕见疾病患者开发治疗方法。该公司的主要候选产品CTI-1601是一种皮下给药的重组融合蛋白，旨在传递一种人体共济失调患者线粒体中的必需蛋白，即frataxin (FXN)。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460241545"}